Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis Pharmaceutical TechnologyBMS has secured approval from the European Commission for Sotyktu (deucravacitinib) to treat active psoriatic arthritis (PsA).Immunology & InflammationRead full story pharminent May 11, 2026 (Last updated: May 11, 2026) Pharmaceutical Technology BMS has secured approval from the European Commission for Sotyktu (deucravacitinib) to treat active psoriatic arthritis (PsA). Immunology & Inflammation Read full story Post navigation Previous: Pulsesight reports positive phase 1 data for PST611 in dry AMDNext: Deal finally unlocks NHS access to ITF’s Duchenne drug Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026